Many patients using GLP-1 agonists are considering microdosing the medication to reduce side effects or extend the duration of therapy. However, is this approach safe? Dr. W. Scott Butsch, a specialist in obesity medicine, warns patients that microdosing is not recommended and explains the potential reasons.
What is Microdosing GLP-1s?
Interest in microdosing GLP-1 drugs has grown in parallel with the increasing use of compounded versions of the latest therapeutic options for weight management. Preparations modeled after the FDA-approved drugs Semaglutide (Wegovy, Ozempic) and Tirzepatide (Zepbound, Mounjaro), but manufactured in pharmacies as master drugs, are receiving increasing attention.
These versions of the drugs are prepared by licensed pharmacists using similar active substances, and their use is justified in situations where standard, approved drugs do not meet the needs of the patient or cause unwanted effects. For example, a drug can be adapted into a different form, a liquid preparation or a cream, for people who have difficulty taking pills.
Microdosing involves knowingly taking a smaller amount of GLP-1 drugs than is usually prescribed. The most common reason for starting this approach is to reduce the therapy costs, as the drug is used for a longer period. In this way, a person prescribed a full dose of Mounjaro 15mg may use a fraction of that amount.
This mode of administration has become particularly widespread during the global obesity drug shortages that occurred shortly after these new, highly effective therapies were introduced to the market and approved in 2021 and 2022.
Dr. Butch noted that microdosing compounded GLP-1 drugs should not be equated with standard dose adjustments of FDA-approved therapies in regular protocols. Dosage adjustment is a common and legitimate medical practice that doctors regularly apply in the treatment of various diseases.
On the other hand, the compounded versions of these drugs have not undergone FDA approval, meaning there is no formal review of their safety, side effects, effectiveness, or quality before they are put into use.
That is why Dr. Butch advises caution and clearly states that he does not recommend using such preparations, as their effects and potential risks have not been sufficiently examined in scientific studies and clinical trials in humans. According to him, the problem is not only whether they work, but also whether they are safe for patients.
Why Do People Microdose GLP-1s?
People may consider microdosing due to:
- Cost
- Side Effects
- Availability
An increasing number of patients who are interested in using GLP-1 drugs for weight control are faced with the fact that health insurance generally does not cover them. This means that therapeutic options like Semaglutide or Tirzepatide often pay for themselves. Although they were initially very expensive and priced unevenly, today they are available through direct manufacturer programs for around $500 per month.
Adverse side effects, such as nausea, diarrhea, and vomiting, lead some patients to self-initiate a reduction in the dose of the drug in the hope of alleviating their symptoms. However, scientists warn that such an approach can have the opposite effect. When the dose is too low, the drug is eliminated from the body faster, so when taking it again, the symptoms often return as the body cannot get used to a stable level of therapy.
The problem is further complicated by occasional drug shortages on the market. Research shows that stopping therapy often leads to weight gain again, even after significant weight loss. As with other therapeutic options, adjusting the dosage and regimen of GLP-1 medications should be a collaborative effort between the patient and physician. Doctors should use their basic knowledge and experience to assess the effectiveness and tolerability of the treatment, and make the decision that is safest and most effective for the patient.
Potential Risks
Microdosing of GLP-1 drugs (reducing the amount of medicine from a bottle or compound preparation) is not the same as adjusting the dose under a doctor’s supervision. People sometimes do this to save money and extend the duration of therapy, but such an approach carries severe risks, including contamination and overdose.
The effects of microdosing have not been adequately studied, so it is unclear how effective or safe this practice is. The body may react differently to a lower dose than the one recommended by the doctor, leading to unwanted consequences.
Experts, like Dr. Butch, stress that there are no official guidelines for microdosing Semaglutide or Tirzepatide. The American Diabetes Association also does not support this practice, so any dosage change should be made only in consultation with a qualified healthcare professional, in accordance with an individualized approach.
Is Microdosing GLP-1s Safe?
The main scientist’s message is simple. Microdosing of GLP-1 drugs has not been studied enough to know how safe or effective it is for the patient’s health. Although microdosing is often discussed on social networks, you should never reduce or change the dose of medication without consulting a doctor.
“A doctor can adjust therapy to suit each patient,” explains Dr. Butch. “It’s not microdosing, it’s expertly and safely tailoring a drug to an individual’s needs based on knowledge.”
